Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs

Guang Hui Liu, Keiichiro Suzuki, Jing Qu, Ignacio Sancho-Martinez, Fei Yi, Mo Li, Sachin Kumar, Emmanuel Nivet, Jessica Kim, Rupa Devi Soligalla, Ilir Dubova, April Goebl, Nongluk Plongthongkum, Ho Lim Fung, Kun Zhang, Jeanne F. Loring, Louise C. Laurent, Juan Carlos Izpisua Belmonte

Research output: Contribution to journalArticlepeer-review

196 Scopus citations


Combination of stem cell-based approaches with gene-editing technologies represents an attractive strategy for studying human disease and developing therapies. However, gene-editing methodologies described to date for human cells suffer from technical limitations including limited target gene size, low targeting efficiency at transcriptionally inactive loci, and off-target genetic effects that could hamper broad clinical application. To address these limitations, and as a proof of principle, we focused on homologous recombination-based gene correction of multiple mutations on lamin A (LMNA), which are associated with various degenerative diseases. We show that helper-dependent adenoviral vectors (HDAdVs) provide a highly efficient and safe method for correcting mutations in large genomic regions in human induced pluripotent stem cells and can also be effective in adult human mesenchymal stem cells. This type of approach could be used to generate genotype-matched cell lines for disease modeling and drug discovery and potentially also in therapeutics.

Original languageEnglish (US)
Pages (from-to)688-694
Number of pages7
JournalCell Stem Cell
Issue number6
StatePublished - Jun 3 2011
Externally publishedYes

Bibliographical note

Funding Information:
We would like to thank K. Mitani, P. Ng, and A. Lieber for kindly providing experimental materials, J. Karlseder, L. Gerace, M. Hetzer, and C. Rodriguez Esteban for helpful discussions, C. Lynch for running SNP genotyping arrays, M.C. Llach for karyotyping, M. Marti for teratoma analysis, Y. Xia and S.-L. Yang for technical help, and M. Schwarz for administrative help. G.-H.L. was partially supported by a CIRM grant (TG2-01158), and J.Q. was partially supported by an AFAR/Ellison Medical Foundation postdoctoral fellowship. E.N. was partially supported by a F.M. Kirby Foundation postdoctoral fellowship. L.C.L. is supported by NIH K12HD001259-11. The work by L.C.L. and J.F.L. was supported by CIRM TR1-01250. This study was supported by grants from DA025779 (K.Z.), the G. Harold and Leila Y. Mathers Charitable Foundation, Sanofi-Aventis, Ellison Medical Foundation, Helmsley Foundation, MICINN, and Fundacion Cellex (J.C.I.B.).

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology


Dive into the research topics of 'Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs'. Together they form a unique fingerprint.

Cite this